Diffuse Intrinsic Pontine GliomaDIPGBrain TumorCNS TumorCentral Nervous System TumorPediatric CancerAdult Cancer PatientsCNS Tumor, ChildhoodCNS Tumor, AdultBrainstem GliomaDiffuse Midline GliomaDMG
Investigational drug(s) / intervention(s)
BCB-276
BCB-276: Following completion of standard radiation therapy, eligible participants with DIPG will undergo leukapheresis, a procedure to collect white blood cells used to manufacture BCB-276, an autologous CAR T cell therapy made from the participant's own immune cells designed to target B7-H3.
All eligible participants will receive up to 15 intraventricular administrations of BCB-276 every 2 weeks for an approximate total duration of 30 weeks.
Study summary
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient's own immune cells that are changed in a laboratory to recognize and attack cancer cells. The purpose of this study is to determine whether BCB-276, when given after completion of standard radiation therapy, is safe and can improve survival for patients with DIPG.
To participate, individuals must be between 1 and 26 years of age when they join the study, have a diagnosis of DIPG, and enroll for treatment within 6 weeks of completing initial radiation therapy. Participants must not have received prior anti-cancer therapy beyond radiation with or without temozolomide prior to joining this study.
BCB-276 is administered intraventricularly (into the fluid around the brain), which requires placement of a catheter for treatment. BCB-276 is given every 2 weeks at a research center over a period of several months (approximately 7-8 months). Participation includes travel to a study site, procedures to support treatment administration, sample collection, and ongoing monitoring for safety and effectiveness, with follow-up visits lasting up to about 2 years.
Eligibility
Sex
ALL
Min age
1 Year
Max age
26 Years
Healthy volunteers
No
Inclusion Criteria:
* Participants must be aged 1 and ≤ 26 years and weigh ≥10kg.
* Diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG) based on imaging, with or without biopsy confirmation consistent with high-grade glioma or diffuse midline glioma
* Able to tolerate leukapheresis and other study procedures in the opinion of the Investigator.
* Central Nervous System (CNS) reservoir catheter present prior to first dose of study drug.
* Participant must have completed standard radiation therapy within 6 weeks of enrollment for participation.
* Performance Status of ≥ 60; mild to moderate restriction or better. Lansky (under 16 years of age) or Karnofsky (16 years of age or older).
* Adequate organ function and overall clinical status to participate, including stable or improving neurologic symptoms.
* Participants of childbearing/fathering potential must agree to use highly effective contraception from the time of enrollment through 12 months following the last T cell infusion.
* Participants with ventriculoperitoneal (VP) shunts need to have a programable system and be able to tolerate temporary adjustment of the shunt required for study treatment.
* Participant must meet all other health and safety criteria defined in the study protocol.
* Participant and/or authorized legal representative willing to provide consent/assent for study participation, including participation in the 15-year long term follow up period.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
* Previous tumor-directed therapy or treatment-directed clinical study other than standard radiation with or without temozolamide.
* Evidence of metastatic disease.
* Requirement of high or increasing doses of corticosteroids prior to participation.
* Severe swallowing difficulties or other significant clinical conditions that may interfere with participation.
* Presence of an active malignancy other than DIPG.
* Active or uncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection based on protocol-required laboratory testing.
* Pregnant or breastfeeding.
* Presence of any condition that, in the Investigator's opinion, would prohibit the participant from undergoing treatment under this protocol.
Primary outcome measure(s)
Overall Survival — Overall Survival (OS) as defined as time from the date of enrollment to death from any cause (up to 24 months from date of enrollment). Up to 24 months from date of enrollment
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.